A Review on Theranostics: An Approach to Targeted Diagnosis and Therapy
DOI:
https://doi.org/10.22270/ajprd.v7i2.463Keywords:
Diagnosis, therapy, theranostics, nuclear medicine, nanomedicineAbstract
Emerging as a targeted, safe, and efficient pharmacotherapy is the approach of theranostics, which focuses on patient centered care. It is a combination of diagnosis and therapeutics. Theranostics is a new field of medicine which combines specific targeted therapy based on specific targeted diagnostic tests. With a key focus on patient centered care, theranostics provides a transition from conventional medicine to a contemporary personalized and precision medicine approach. The theranostics paradigm involves using nanoscience to unite diagnostic and therapeutic applications to form a single agent, allowing for diagnosis, drug delivery and treatment response monitoring. The theranostics medicine can achieve systemic circulation, evade host defenses and deliver the drug and diagnostic agents at the targeted site to diagnose and treat the disease at cellular and molecular level.
Downloads
References
2. Jeelani S, Reddy RC, Maheswaran T, Asokan GS, Dany A, Anand B. Theranostics: A treasured tailor for tomorrow, J Pharm Bioallied Sci. 2014 ;6(1):S6-8.
3. Madaswamy S. Muthu, David Tai Leong, Lin Mei, Si-Shen Feng. Nanotheranostics ˗ Application and Further Development ofNanomedicine Strategies for Advanced Theranostics, Theranostics 2014; 4(6):660-677.
4. Ken Herrmann, Steven M. Larson and Wolfgang A. Weber. TheranosticConcepts: More Than Justa Fashion Trend—Introduction andOverview. J Nucl Med, 2017; 58(2).
5. Anna Y, Elisabeth E, Stefan K, Ralph AB, Stefan S, Maria GC, Georg F, Hojjat A, Markus E. Theranostics in nuclear medicine practice. OncoTargets and Therapy: Dovepress, 2017;10
6. Warland S, Hesse M, Renauld L, Jumar F. The impact of image reconstruction bias on PET/CT90 Y dosimetry after radioemobilisation. J Nucl Med, 2015; 56(3):494-495.
7. LusterM, Clarke S.E, Dietlein M, Lassmann M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008; 35(10):1941-1949.
8. Sonali, Viswanadh MK, Singh RP, Agrawal P, Mehata AK, Pawde DM, Narendra , Sonkar R, Muthu MS. Nanotheranostics: Emerging Strategies for Early Diagnosis and Therapy of Brain Cancer. Nanotheranostics 2018; 2(1):70-86.
9. Shapiro A, Livney YD, broxterman HJ, Assaraf YG. Nanomedicine for Targeted Cancer Therapy: towards the overcoming of drug resistance. Drug Resist Update 2011; 14(3):150-163.
10. mmy D.G. Fleuren, Yvonne M.H., Versleijen-Jonkers, Sandra Heskamp, Carla M.L. van Herpen,Wim J.G. Oyen, Winette T.A. van der Graaf, and Otto C. Boerman. Theranostic applications of antibodies in oncology. Mol Oncol. 2014; 8(4): 799–812.
11. Hegdekar CN. Nanotechnology and the theranostic approach for the future management of cancer and the ethics of nanomedicine. 2010, medlink-uk.net.
12. Nimita L. Pharmacogenomics, Theranostics and Personalised medicine- The complexities of clinical trials: challenges in the developing world. Appl Transl Genomics, 2013; 2:17-21.
13. Santra S. The potential clinical impact of quantum dots. Nanomedicine (Lond). 2012; 7(5):623-626.
14. Feng Chen, Emily B. Ehlerding and Weibo Cai. Theranostic Nanoparticles. J Nucl Med. 2014 Dec; 55(12): 1919–1922.
15. Bhattarai N, Bhattarai SR. Therapeutic nanoparticles: A recent breakthrough in Nanotechnology. J Nanomed Nanotechnol. 2012; 3:e114.
16. Sairamesh J, Michael R. An economic perspective on personalized medicine. Hugo J. 2013; 7:1.
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.